Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases

Activation of androgen receptor (AR) may have a role in the development of castration-resistant prostate cancer. Two intracellular tyrosine kinases, Ack1 (activated cdc42-associated kinase) and Src, phosphorylate and enhance AR activity and promote prostate xenograft tumor growth in castrated animals. However, the upstream signals that activate these kinases and lead to AR activation are incompletely characterized. In this study, we investigated AR phosphorylation in response to non-androgen ligand stimulation using phospho-specific antibodies. Treatment of LNCaP and LAPC-4 cells with epidermal growth factor (EGF), heregulin, Gas6 (ligand binding to the Mer receptor tyrosine kinase and activating Ack1 downstream), interleukin (IL)-6 or bombesin stimulated cell proliferation in the absence of androgen. Treatment of LNCaP and LAPC-4 cells with EGF, heregulin or Gas6 induced AR phosphorylation at Tyr-267, whereas IL-6 or bombesin treatment did not. AR phosphorylation at Tyr-534 was induced by treatment with EGF, IL-6 or bombesin, but not by heregulin or Gas6. Small interfering RNA-mediated knockdown of Ack1 or Src showed that Ack1 mediates heregulin- and Gas6-induced AR Tyr-267 phosphorylation, whereas Src mediates Tyr-534 phosphorylation induced by EGF, IL-6 and bombesin. Dasatinib, a Src inhibitor, blocked EGF-induced Tyr-534 phosphorylation. In addition, we showed that dasatinib also inhibited Ack1 kinase. Dasatinib inhibited heregulin-induced Ack1 kinase activity and AR Tyr-267 phosphorylation. In addition, dasatinib inhibited heregulin-induced AR-dependent reporter activity. Dasatinib also inhibited heregulin-induced expression of endogenous AR target genes. Dasatinib inhibited Ack1-dependent colony formation and prostate xenograft tumor growth in castrated mice. Interestingly, Ack1 or Src knockdown or dasatinib did not inhibit EGF-induced AR Tyr-267 phosphorylation or EGF-stimulated AR activity, suggesting the existence of an additional tyrosine kinase that phosphorylates AR at Tyr-267. These data suggest that specific tyrosine kinases phosphorylate AR at distinct sites and that dasatinib may exert antitumor activity in prostate cancer through inhibition of Ack1.

[1]  R. Vessella,et al.  Molecular determinants of resistance to antiandrogen therapy , 2004, Nature Medicine.

[2]  Nicholas Bruchovsky,et al.  Ligand-independent Activation of the Androgen Receptor by Interleukin-6 and the Role of Steroid Receptor Coactivator-1 in Prostate Cancer Cells* , 2002, The Journal of Biological Chemistry.

[3]  F. S. French,et al.  Epidermal Growth Factor Increases Coactivation of the Androgen Receptor in Recurrent Prostate Cancer* , 2004, Journal of Biological Chemistry.

[4]  J. Kreisberg,et al.  Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer. , 2007, Current cancer drug targets.

[5]  T. Vomastek,et al.  Receptor for activated C kinase 1 (RACK1) and Src regulate the tyrosine phosphorylation and function of the androgen receptor. , 2006, Cancer research.

[6]  A. Armstrong,et al.  Dasatinib and docetaxel combination treatment for patients with castration-resistant progressive prostate cancer: A phase I/II study (CA180086). , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  H. Scher,et al.  Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Pao-Chun Lin,et al.  Cytoplasmic ACK1 Interaction with Multiple Receptor Tyrosine Kinases Is Mediated by Grb2 , 2009, The Journal of Biological Chemistry.

[9]  A. Brinkmann,et al.  Androgen receptor phosphorylation. , 1996, Endocrine research.

[10]  C. Tepper,et al.  Inappropriate activation of the androgen receptor by nonsteroids: involvement of the Src kinase pathway and its therapeutic implications. , 2006, Cancer research.

[11]  Christophe Massard,et al.  Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer , 2009, Clinical Cancer Research.

[12]  J. Schlessinger,et al.  Activation of the nonreceptor protein tyrosine kinase Ack by multiple extracellular stimuli. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[13]  J. Shabanowitz,et al.  Androgen Receptor Phosphorylation , 2002, The Journal of Biological Chemistry.

[14]  F. S. French,et al.  Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. , 2001, Cancer research.

[15]  F. S. French,et al.  Site-specific Androgen Receptor Serine Phosphorylation Linked to Epidermal Growth Factor-dependent Growth of Castration-recurrent Prostate Cancer* , 2008, Journal of Biological Chemistry.

[16]  Zhengxin Wang,et al.  Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. , 2008, Cancer research.

[17]  Zhiyong Guo,et al.  Regulation of androgen receptor activity by tyrosine phosphorylation. , 2006, Cancer cell.

[18]  M. Stratton,et al.  COSMIC 2005 , 2006, British Journal of Cancer.

[19]  J. Mohler,et al.  Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer. , 2005, Cancer research.

[20]  N. Bruchovsky,et al.  Activation of the Androgen Receptor N-terminal Domain by Interleukin-6 via MAPK and STAT3 Signal Transduction Pathways* , 2002, The Journal of Biological Chemistry.

[21]  C. Logothetis,et al.  Targeting Src signaling in metastatic bone disease , 2009, International journal of cancer.

[22]  K. A. Klein,et al.  Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice , 1997, Nature Medicine.

[23]  William Pao,et al.  Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Desok Kim,et al.  Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. , 1998, Cancer research.

[25]  James L Mohler,et al.  Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role of Ack1 in polyubiquitination of tumor suppressor Wwox. , 2005, Cancer research.

[26]  J. Mohler,et al.  Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation , 2007, Proceedings of the National Academy of Sciences.

[27]  S. Parsons,et al.  The neuroendocrine-derived peptide parathyroid hormone-related protein promotes prostate cancer cell growth by stabilizing the androgen receptor. , 2009, Cancer research.

[28]  B. E. Black,et al.  Stress kinase signaling regulates androgen receptor phosphorylation, transcription, and localization. , 2006, Molecular endocrinology.

[29]  R. Matusik,et al.  A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. , 2000, Endocrinology.

[30]  R. Pestell,et al.  Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells , 2006, Oncogene.

[31]  Ingo K Mellinghoff,et al.  HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. , 2004, Cancer cell.

[32]  A. Borowsky,et al.  Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer. , 2009, Cancer research.

[33]  S. Powers,et al.  Metastatic properties and genomic amplification of the tyrosine kinase gene ACK1. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[34]  H. Kung,et al.  Neuropeptide-Induced Androgen Independence in Prostate Cancer Cells: Roles of Nonreceptor Tyrosine Kinases Etk/Bmx, Src, and Focal Adhesion Kinase , 2001, Molecular and Cellular Biology.

[35]  R. Pazdur,et al.  Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate , 2008, Clinical Cancer Research.

[36]  F. S. French,et al.  Heregulin-Induced Activation of HER2 and HER3 Increases Androgen Receptor Transactivation and CWR-R1 Human Recurrent Prostate Cancer Cell Growth , 2005, Clinical Cancer Research.